ProMIS Neurosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PMN Nasdaq 2836 www.promisneurosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ProMIS Neurosciences, Inc.

ProMIS Neurosciences to Participate in Upcoming Conferences in November - Nov 5th, 2026 5:00 am
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates - Nov 4th, 2026 6:38 am
Can Pharmacy Growth Offset Evernorth's Profit Decline in Cigna's Q3? - Nov 3rd, 2026 6:17 am
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026 - Nov 3rd, 2026 5:00 am
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade - Oct 29th, 2026 6:55 am
Will HCA Healthcare's Q3 Earnings Benefit From Higher Admissions? - Oct 22nd, 2026 5:40 am
Can Higher Admissions Offset Rising Costs in UHS' Q3 Earnings? - Oct 21st, 2026 6:36 am
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer - Oct 6th, 2026 5:05 am
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - Sep 1st, 2026 6:00 am
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... - Aug 13th, 2026 11:02 pm
Promis Neurosciences Q2 Earnings Call Highlights - Aug 13th, 2026 8:04 pm
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - Aug 13th, 2026 2:00 pm
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - Aug 3rd, 2026 2:00 pm
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data - Jul 28th, 2026 12:04 pm
ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results - Jul 28th, 2026 6:25 am
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial - Jul 28th, 2026 4:00 am
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease - Jul 27th, 2026 2:00 pm
Can Acute Care Strength Offset Universal Health's Rising Q2 Costs? - Jul 23rd, 2026 10:44 am
Will Lower Patient Days Affect Tenet Healthcare's Q2 Earnings? - Jul 21st, 2026 9:44 am
Will Higher Expenses Impact HCA Healthcare's Q2 Earnings? - Jul 20th, 2026 10:13 am